Substance / Medication

Rilpivirine

Overview

Active Ingredient
rilpivirine
RxNorm CUI
1102270

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

10 trials linked to this intervention

10
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta-analysis.
Barda Beatrice, Barilaro Giuseppe, Bellini Paola et al. · HIV Med · 2025
PMID: 40204512Meta-Analysis
Cabotegravir Plus Rilpivirine Injection for Virally Suppressed Persons with HIV-1 infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Hedima Erick Wesley, Ohieku John David, Nasir Abdulrahman et al. · Clin Ther · 2025
PMID: 40517074Meta-Analysis
Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
Allen Reeves Anthony, Fuentes Andrea V, Caballero Joshua et al. · Sex Transm Infect · 2021
PMID: 33782144Meta-Analysis
Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.
Vannappagari Vani, Ragone Leigh, Henegar Cassidy et al. · Antivir Ther · 2019
PMID: 31503008Meta-Analysis
Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.
Calvez Vincent, Marcelin Anne-Genevieve, Vingerhoets Johan et al. · Antivir Ther · 2016
PMID: 26761642Meta-Analysis
Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
Tan Darrell H S, Antinori Andrea, Eu Beng et al. · J Acquir Immune Defic Syndr · 2025
PMID: 39676239RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rilpivirine (substance)
SNOMED CT
703123005
UMLS CUI
C1566826
RxNorm CUI
1102270

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
10
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.